We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+35.64%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$291M
AUM Growth
+$25.4M
Cap. Flow
-$37.9M
Cap. Flow %
-13.02%
Top 10 Hldgs %
53.99%
Holding
96
New
7
Increased
8
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$6.64M
2
AFMD
Affimed
AFMD
+$3.03M
3
STIM icon
Neuronetics
STIM
+$1.8M
4
OTIC
Otonomy, Inc.
OTIC
+$1.15M
5
KURA icon
Kura Oncology
KURA
+$1.03M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$12M
2
WVE icon
Wave Life Sciences
WVE
+$3.94M
3
ASND icon
Ascendis Pharma A/S
ASND
+$3.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$3.57M
5
ARDX icon
Ardelyx
ARDX
+$2.31M

Sector Composition

Rank Sector Weight
1 Healthcare 91.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAT
26
DELISTED
BioTelemetry, Inc.
BEAT
$2.56M 0.88%
55,300
+10,000
+22% +$433K
ALEC icon
27
Alector
ALEC
$168M
$2.5M 0.86%
145,000
– –
KURA icon
28
Kura Oncology
KURA
$800M
$2.38M 0.82%
173,475
+69,817
+67% +$1.03M
CSII
29
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.25M 0.77%
46,200
– –
BLUE
30
DELISTED
bluebird bio
BLUE
$2.24M 0.77%
1,969
– –
PHAS
31
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.2M 0.76%
360,542
– –
ARAY icon
32
Accuray
ARAY
$32M
$1.9M 0.65%
674,300
– –
TPTX
33
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.89M 0.65%
30,408
-16,900
-36% -$804K
ARCT icon
34
Arcturus Therapeutics
ARCT
$164M
$1.89M 0.65%
173,914
– –
OTIC
35
DELISTED
Otonomy, Inc.
OTIC
$1.8M 0.62%
+469,135
New +$1.15M
STIM icon
36
Neuronetics
STIM
$138M
$1.78M 0.61%
395,772
+289,525
+273% +$1.8M
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2.28B
$1.77M 0.61%
514,051
+30,663
+6% +$77.1K
KDMN
38
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.7M 0.58%
374,423
-511,754
-58% -$1.87M
VKTX icon
39
Viking Therapeutics
VKTX
$3.7B
$1.68M 0.58%
209,200
– –
EPZM
40
DELISTED
Epizyme, Inc
EPZM
$1.67M 0.57%
68,000
-53,986
-44% -$801K
MGNX icon
41
MacroGenics
MGNX
$235M
$1.63M 0.56%
150,000
-50,000
-25% -$495K
AGTC
42
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.62M 0.56%
359,190
– –
CRBP icon
43
Corbus Pharmaceuticals
CRBP
$166M
$1.62M 0.56%
9,910
– –
INGN icon
44
Inogen
INGN
$175M
$1.57M 0.54%
23,000
– –
ELOX
45
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$1.51M 0.52%
5,146
-4,229
-45% -$852K
ARDX icon
46
Ardelyx
ARDX
$1.22B
$1.5M 0.51%
199,850
-380,674
-66% -$2.31M
TBIO
47
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$1.46M 0.5%
179,845
-184,384
-51% -$1.7M
NTUS
48
DELISTED
Natus Medical Inc
NTUS
$1.42M 0.49%
42,900
– –
JNJ icon
49
Johnson & Johnson
JNJ
$618B
$1.37M 0.47%
9,400
– –
AUTL
50
Autolus Therapeutics
AUTL
$397M
$1.32M 0.45%
100,000
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, DAFNA Capital Management held 96 positions worth $291M, up 9.6% from $266M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DAFNA Capital Management withdrew a net $37.9M in Q4 2019, closing 15 positions and reducing 27 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Affimed worth $3.11M.

  • DAFNA Capital Management's largest Q4 2019 buy was Affimed: 113,356 shares worth $3.11M.
  • DAFNA Capital Management added most to ProQR Therapeutics in Q4 2019, an estimated $6.64M increase.
  • DAFNA Capital Management's biggest Q4 2019 reduction was Wave Life Sciences, cutting an estimated $3.94M.
  • DAFNA Capital Management fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $12M.
  • DAFNA Capital Management's ten largest holdings make up 54% of its $291M portfolio in Q4 2019.
  • DAFNA Capital Management opened 7 new positions and closed 15 in Q4 2019.
  • DAFNA Capital Management's portfolio value rose 9.6% quarter-over-quarter to $291M.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.